Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016

  • ID: 3984504
  • Report
  • 45 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Galapagos NV
  • Merck & Co Inc
  • Syntiron LLC
  • Valevia UK Ltd
  • MORE
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016, provides an overview of the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Predisposing factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA may be managed by the use of antibiotics and by maintaining hygienic conditions.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 4 respectively.Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections.

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Galapagos NV
  • Merck & Co Inc
  • Syntiron LLC
  • Valevia UK Ltd
  • MORE
List of Tables

List of Figures

Introduction

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections Overview

Therapeutics Development

Pipeline Products for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Overview

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Therapeutics under Development by Companies

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Products under Development by Companies

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Companies Involved in Therapeutics Development

Allergan Plc

Galapagos NV

Merck & Co Inc

Syntiron LLC

Valevia UK Ltd

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

acorafloxacin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLPG-1492 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Staphylococcus aureus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Allergan Plc, H2 2016

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Galapagos NV, H2 2016

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Merck & Co Inc, H2 2016

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Syntiron LLC, H2 2016

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Valevia UK Ltd, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Dormant Projects, H2 2016

List of Figures

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections, H2 2016

Number of Products under Development by Companies, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Galapagos NV
  • Merck & Co Inc
  • Syntiron LLC
  • Valevia UK Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll